Dentsply Sirona Inc.

XRAY

Nasdaq; healthcare; SIC 3843, Dental Equipment & Supplies; CIK 0000818479

D

fourth fifth of 369 graded peers in healthcare

rank 245 of 369; percentile 66.3; sampling error 2.5 points; lower is stronger

A B C D E

D, the sloth



Scoreboard	
Profitability	B percentile 35.2
Solvency	C/D percentile 59.3
Growth and financing	D percentile 65.1
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $5.4B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	9 of 14
Graded from	filings received through Feb 26, 2026 259 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$9.77 2026-11-11; market equity $1.9B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") is the world's largest diversified manufacturer of professional dental products and technologies, with a 139-year history of innovation and service to the dental industry and a vision of improving oral health and continence care globally. Dentsply Sirona develops, manufactures, and markets comprehensive solutions, including technologically advanced dental equipment supported by cloud-enabled software solutions as well as dental products and healthcare consumable products in urology and enterology under a strong portfolio of world-class brands.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 35.2						
Gross profitability	33.9%	32.3%		41.5	365	2025-12-31
Return on invested capital	not computable	9.3%				

pretax income must exceed the validity floor and imply a 0%-100% tax rate

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(14.9%)	(6.6%)	29.8	801	2025-12-31
Gross margin stability, five years	1.9 pts	2.8 pts	34.4	242	2025-12-31
Solvency, sleeve percentile 59.3					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(0.30)	(0.35)	37.6	745	2025-12-31
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	1.51x	2.95x	81.0	827	2025-12-31
Growth and financing, sleeve percentile 65.1					
Revenue growth, three-year compound	(2.1%)	10.1%	76.2	412	2025-12-31
Free cash flow growth, three-year compound	(34.4%)	11.0%	96.8	95	2025-12-31
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	(10.8%)	2.2%	70.5	695	2025-12-31
Net share issuance, one year	0.4%	2.5%	17.1	628	2026-02-20

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
240	Organogenesis Holdings Inc. (ORGO)	64.9	D	fortress balance sheet
241	Pulse Biosciences, Inc. (PLSE)	65.2	D	
242	Entera Bio Ltd. (ENTX)	65.5	D	degenerate inputs
243	AIM ImmunoTech Inc. (AIM)	65.8	D	late filer, degenerate inputs, distress
244	Fulgent Genetics, Inc. (FLGT)	66.0	D	
245	Dentsply Sirona Inc. (XRAY)	66.3	D	
246	Caribou Biosciences, Inc. (CRBU)	66.6	D	short runway
247	Angiodynamics Inc. (ANGO)	66.8	D	fortress balance sheet
248	InspireMD, Inc. (NSPR)	67.1	D	dilution, short runway, distress
249	Exagen Inc. (XGN)	67.4	D	dilution, fortress balance sheet
250	Alpha Teknova, Inc. (TKNO)	67.7	D	

What the price implies

at the 2026-11-11 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(28.7%)	(1.9%)	31
Distance from 52-week high	(33.5%)	(27.8%)	44
EBIT to enterprise value	(10.5%)	(1.6%)	34
Free cash flow yield	5.4%	(1.0%)	84
Book value to price	0.70	0.27	78

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Sales to price	1.90	0.29	90
Composite equity issuance, five years	(21.1%)	20.8%	8
Relative strength against the sector, log excess return	(0.51)	(0.19)	31

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$195.0M
Operating cash flow, four quarters	$272.0M
Months of runway	not finite
Days since last periodic filing	7 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$40.2M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$1.8B	2025-12-31	2026-02-26	10-K	26-000075
2	assets	us-gaap:Assets	$5.4B	2025-12-31	2026-02-26	10-K	26-000075
3	operating income	us-gaap:OperatingIncomeLoss	-$422.0M	2025-12-31	2026-02-26	10-K	26-000075
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$486.0M	2025-12-31	2026-02-26	10-K	26-000075
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$112.0M	2025-12-31	2026-02-26	10-K	26-000075
6	total debt	us-gaap:LongTermDebt	$2.3B	2025-12-31	2026-02-26	10-K	26-000075
7	book equity	us-gaap:StockholdersEquity	$1.3B	2025-12-31	2026-02-26	10-K	26-000075
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$326.0M	2025-12-31	2026-02-26	10-K	26-000075
9	total debt	us-gaap:LongTermDebt	$1.7B	2024-12-31	2025-02-27	10-K	25-000035
10	book equity	us-gaap:StockholdersEquity	$1.9B	2024-12-31	2026-02-26	10-K	26-000075
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$272.0M	2024-12-31	2026-02-26	10-K	26-000075
12	net income	us-gaap:NetIncomeLoss	-$598.0M	2025-12-31	2026-02-26	10-K	26-000075
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$235.0M	2025-12-31	2026-02-26	10-K	26-000075
14	assets	us-gaap:Assets	$5.8B	2024-12-31	2026-02-26	10-K	26-000075
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.7B	2025-12-31	2026-02-26	10-K	26-000075
16	gross profit	us-gaap:GrossProfit	$2.0B	2024-12-31	2026-02-26	10-K	26-000075
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.8B	2024-12-31	2026-02-26	10-K	26-000075
18	gross profit	us-gaap:GrossProfit	$2.1B	2023-12-31	2026-02-26	10-K	26-000075
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$4.0B	2023-12-31	2026-02-26	10-K	26-000075
20	gross profit	us-gaap:GrossProfit	$2.1B	2022-12-31	2025-02-27	10-K	25-000035
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.9B	2022-12-31	2025-02-27	10-K	25-000035
22	gross profit	us-gaap:GrossProfit	$2.3B	2021-12-31	2024-02-29	10-K	24-000021
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$4.2B	2021-12-31	2024-02-29	10-K	24-000021
24	current assets	us-gaap:AssetsCurrent	$2.0B	2025-12-31	2026-02-26	10-K	26-000075
25	current liabilities	us-gaap:LiabilitiesCurrent	$1.3B	2025-12-31	2026-02-26	10-K	26-000075
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.6B	2025-12-31	2026-02-26	10-K	26-000075
27	liabilities	us-gaap:Liabilities	$4.1B	2025-12-31	2026-02-26	10-K	26-000075

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$352.0M	2025-12-31	2026-02-26	10-K	26-000075
29	operating income	us-gaap:OperatingIncomeLoss	-$85.0M	2023-12-31	2026-02-26	10-K	26-000075
30	interest expense	us-gaap:InterestExpense	$81.0M	2023-12-31	2024-02-29	10-K	24-000021
31	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$131.0M	2025-12-31	2026-02-26	10-K	26-000075
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$461.0M	2024-12-31	2026-02-26	10-K	26-000075
33	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$180.0M	2024-12-31	2026-02-26	10-K	26-000075
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$377.0M	2023-12-31	2026-02-26	10-K	26-000075
35	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$149.0M	2023-12-31	2026-02-26	10-K	26-000075
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$517.0M	2022-12-31	2025-02-27	10-K	25-000035
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$149.0M	2022-12-31	2023-08-07	10-K/A	23-000062
38	current assets	us-gaap:AssetsCurrent	$1.7B	2024-12-31	2026-02-26	10-K	26-000075
39	current liabilities	us-gaap:LiabilitiesCurrent	$1.6B	2024-12-31	2026-02-26	10-K	26-000075
40	assets	us-gaap:Assets	$7.4B	2023-12-31	2025-02-27	10-K	25-000035
41	assets	us-gaap:Assets	$7.6B	2022-12-31	2024-02-29	10-K	24-000021
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	199,749,333	2026-02-20	2026-02-26	10-K	26-000075
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	198,991,963	2025-02-14	2025-02-27	10-K	25-000035

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.